Search

Zealand Pharma A-S

Cerrado

421.2 -0.73

Resumen

Variación precio

24h

Actual

Mínimo

416.7

Máximo

433.4

Métricas clave

By Trading Economics

Ingresos

-25M

-291M

Ventas

4.6M

9.1M

BPA

-4.12

Margen de beneficio

-3,213.715

Empleados

335

EBITDA

8.1M

-253M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 meses

+25.15% upside

Dividendos

By Dow Jones

Próximas Ganancias

15 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-20B

30B

Apertura anterior

421.93

Cierre anterior

421.2

Zealand Pharma A-S Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

12 mar 2025, 09:23 UTC

Principales Movimientos del Mercado

Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche

20 dic 2024, 09:22 UTC

Principales Movimientos del Mercado

Zealand Pharma Shares Fall After FDA Pushes Back Bowel-Disease Drug

12 mar 2025, 16:34 UTC

Principales Noticias

Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal -- Update

12 mar 2025, 08:18 UTC

Charlas de Mercado

Roche's Obesity Deal With Zealand Pharma Makes Sense, Vontobel Says -- Market Talk

Zealand Pharma A-S Esperado

Precio Objetivo

By TipRanks

25.15% repunte

Estimación a 12 meses

Media 270.582 DKK  25.15%

Máximo 270.568 DKK

Mínimo 270.568 DKK

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Zealand Pharma A-S Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

1 ratings

0

Comprar

1

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Zealand Pharma A-S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.